RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on RegenXBio (RGNX – Research Report), with a price target of $24.00.

Judah Frommer has given his Buy rating due to a combination of factors that highlight RegenXBio’s promising developments in their gene therapy pipeline. The recent interim data from the RGX-202 Phase 1/2 AFFINITY DUCHENNE trial indicates a potential functional benefit, with a biomarker and safety profile that seems to surpass the current standard of care. This positive outlook is further supported by management’s confidence in the trial’s progression and the possibility of an accelerated approval pathway for Duchenne Muscular Dystrophy (DMD).
Moreover, the company’s diversified mid- to late-stage gene therapy pipeline, along with its strong financial position bolstered by non-dilutive financings, provides additional downside protection. The updated functional data from the trial shows improvement in patients who were expected to be in the decline phase of DMD, outperforming natural history controls. This, combined with ongoing pivotal trial enrollment and anticipated topline data in the first half of 2026, strengthens the investment thesis for RegenXBio.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.

RGNX’s price has also changed slightly for the past six months – from $8.740 to $8.360, which is a -4.35% drop .